Pacific Biosciences of Californi (NASDAQ: PACB) stock enjoyed a major increase of 12.1% on 11/14/23. The shares closed at $7.22. The stock has been weak relative to the market over the last nine months but has risen 6.2% during the last week.
Current PriceTarget Research Rating
PACB’s future returns on capital are forecasted to be in line with the cost of capital. Accordingly, the company is expected to continue to be Value Creation neutral.
Pacific Biosciences of Californi has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. Pacific Biosciences of Californi has a neutral Power Rating of 41 but a very low Appreciation Score of 12, leading to the Lowest Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment